

AN IMPORTANT MESSAGE TREATING CANCER

Clinical studies indicate that Ativan® (lorazepam) Injection can play a significant role in enhancing patient tolerance for and acceptance of chemotherapy.¹⁻⁵ In studies comparing Ativan Injection to other adjunctive agents, patients expressed a strong preference for the regimen including Ativan Injection because of its anxiolytic, amnesic and sedative effects.^{2,4}

The reduction of recall following administration of Ativan Injection was considered by most patients to be not only acceptable, but also desirable.¹⁻⁵ Furthermore, due to its anxiolytic action, Ativan Injection was helpful in relieving the anxiety associated with the stresses of chemotherapy.^{3,4}

NEW ADJUNCTIVE AGENTS NEEDED

A study of 52 mastectomy patients on regimens of cyclophosphamide, methotrexate and 5-FU (CMF) revealed that over one fourth of patients failed to even complete a treatment course of 12 to 18 months, mostly because of the side effects associated with these agents.⁶ A recent survey of 56 oncology centers found up to 10% of patients refused further chemotherapy because of actual or feared side effects.⁷ Statistics such as these have spurred researchers to seek new adjunctive agents or combinations of existing agents that would increase the tolerability of chemotherapy.

ATIVAN® INJECTION: A SUPPORTIVE ADJUNCT

In a study involving 18 patients receiving 36 courses of *cis*-platinum therapy, Ativan Injection was administered prior to therapy. Lack of recall for the chemotherapy infusion, and for the subsequent 8 hours, was reported

in 33 of 36 courses of therapy studied. Furthermore, amnesia for the day of chemotherapy was reported in 29 courses. All 18 patients believed the lack of recall was highly desirable.⁵

Dr. John Laszlo and colleagues from Duke Comprehensive Cancer Center, Durham, NC, and Memorial Sloan-Kettering Institute, New York, reported a pilot study involving 32 patients receiving cisplatin with or without other cytotoxic chemotherapy and adjunctive use of Ativan Injection.³ Thirty patients were evaluated over 45 courses of treatment (two were eliminated for protocol violations).

Dr. Laszlo observed that following lorazepam, recall of the day's events was reduced for most patients. Post-treatment anxiety was also reduced. Almost all of the patients in the study requested lorazepam (Ativan Injection) pretreatment again for subsequent chemotherapy courses, regardless of incidence or intensity of emetic episodes. From this study, Dr. Laszlo concluded that lorazepam can be an effective agent for these patients.

FOR PHYSICIANS PATIENTS

A SIGNIFICANT ROLE IN ENHANCING COMPLIANCE IN CHEMOTHERAPY

Clearly, Ativan® (lorazepam) Injection represents an important supportive adjunct in chemotherapy. Patients' ability to tolerate the experience is usually enhanced. Their acceptance of a regimen incorporating Ativan Injection has been excellent. Thus, it is felt that many patients who might otherwise abandon treatment may now be more willing to proceed with Ativan Injection as an adjunct in their chemotherapy regimen.

If outpatients are treated with lorazepam injection, care must be taken on the day of treatment to prevent their undertaking any activity requiring full awareness or coordination.

REFERENCES:

1. Maher J: Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy (letter to the editor). *Lancet* 1:91-92, 1981.
2. Gagen M, Gochmour D, Young D, et al: A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting. *J Clin Oncol* 2:696-701, 1984.
3. Laszlo J, Clark RA, Hanson DC, et al: Lorazepam in patients treated with cisplatin: A drug having antiemetic, amnesic and anxiolytic effects. Presented at the meeting of the ASCO, San Diego, CA, May 23, 1983.
4. Bowcock SJ, Stockdale AD, Bolton JAR, et al: Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. *Br Med J* 288:1879, 1984.
5. Semrad NF, Leuchter RS, Townsend DE, et al: A pilot study of lorazepam-induced amnesia with *cis*-platinum-containing chemotherapy. *Gynecol Oncol* 17:277-280, 1984.
6. Wilcox PM, Fetting JH, Nettesheim KM, et al: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. *Cancer Treat Rep* 66:1601-1604, 1982.
7. Maule WF, Perry MC: Management of chemotherapy-induced nausea and emesis. *Am Fam Physician* 27:226-234, 1983.

Please see important information on the following page.


Laszlo J (ed): Proceedings of an investigational review—June 10, 1983—Lorazepam as an adjunct in cancer chemotherapy. *Oncology Times* (Suppl): February 1985.

This supplement reviews the experience of five leaders in oncology using Ativan Injection as an adjunct in chemotherapy. You may request the supplement by writing to Medical Communications, Wyeth Laboratories, P.O. Box 8299, Philadelphia, PA 19101. We will be pleased to fulfill your request at no charge.

ATIVAN® (LORAZEPAM) 
INJECTION  I.V.

Wyeth Laboratories
Philadelphia, PA 19101

TM



**This
publication is
available in
microform.**

University Microfilms International reproduces this publication in microform: microfiche and 16mm or 35mm film. For information about this publication or any of the more than 13,000 titles we offer, complete and mail the coupon to: University Microfilms International, 300 N. Zeeb Road, Ann Arbor, MI 48106. Call us toll-free for an immediate response: 800-521-3044. Or call collect in Michigan, Alaska and Hawaii: 313-761-4700.

**University
Microfilms
International**

Please send information about these titles:

Name _____

Company/Institution _____

Address _____

City _____ State _____ Zip _____

Phone (_____) _____

Announcement

European School of Oncology Award for Outstanding Research in Cancer Chemotherapy



The European School of Oncology announces an award of \$15,000 for research in cancer chemotherapy. The purpose of the award is to recognize outstanding achievement in cancer chemotherapy research and to provide financial assistance to candidates working in this field.

Eligibility

This Award is open to European Oncologists under the age of 35 years, working in the field of clinical or experimental cancer chemotherapy.

resumé of the Candidate's career. A full curriculum vitae shall be submitted and copies of recent, relevant publications.

Applications

Applications are invited for the ESO Oncology Award. Candidates should submit a statement of not more than 500 words, which includes a summary of background, work achieved and future proposals. The Candidate's submission should be supplemented by a letter of endorsement by the Institute Director, or Departmental Head, which includes a

Award Lecture

The selection of the Award winner will be made by the "ESO Award" Selection Committee at the end of March, 1986. Presentation of the Award will be made at the 14th International Conference to be held in Budapest in August, 1986. The winner will give a plenary lecture during the Conference.



This award is made possible by an educational grant presented by Lederle Laboratories, A Division of American Cyanamid Company, Wayne, New Jersey, USA

European School of Oncology postgraduate courses in medical oncology 1986

10-14 March	Paediatric oncology, Chairman: P.A. Voûte (Amsterdam)
21-25 April	Cancer nursing, Chairman: R. Tiffany (London)
9-13 June	Principles and practice of radiotherapy, Chairman: M. Peckham (London)
30 June-5 July	Medical oncology, Chairman: H.M. Pinedo (Amsterdam)
18-20 Aug.	Nutrition and cancer, Chairman: F. Bozzetti (Milan) Budapest, in conjunction with UICC World Congress
18-21 Aug.	Oesophageal cancer, Chairman: R. Giuli (Paris) Budapest, in conjunction with UICC World Congress
8-12 Sept.	Leukaemia, Chairman: R. Zittoun (Paris)
6-10 Oct.	Breast cancer, Chairman: U. Veronesi (Milan)

For information, write: Secretariat:
E.S.O. European School of Oncology
Via G. Venezian, 1-20133 Milan—Italy



When someone in your family gets cancer, everyone in your family needs help.

Nobody knows better than we do how much help and understanding is needed for the family of a cancer patient. The patient's spouse is under tremendous stress, and the children are often forgotten or just plain left out. That's why our service and rehabilitation programs emphasize the whole family, not just the cancer patient.

We run local programs nationwide with millions of volunteers whose lives have been touched by family members or friends with cancer or who themselves are recovered cancer patients. That's what makes the American Cancer Society one of the largest, best

motivated and most caring of any health organization in the country.

Among our regular services we provide information and guidance to patients and families, transport patients to and from treatment, supply home care items and assist patients in their return to everyday life.

Life is what concerns us. The life of cancer patients. The lives of their families.

So you can see we are even more than the research organization we are so well known to be.

No one faces
cancer alone.

AMERICAN CANCER SOCIETY